16th Annual NATA Symposium

16th Annual NATA Symposium, Prague 2015The 16th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Prague Congress Centre in Prague, Czech Republic, on April 16-17, 2015.

The first announcement can be downloaded in PDF or Powerpoint format.

The preliminary scientific programme is now availble, and the deadline for abstract submission is December 19, 2014.

More information on the Annual NATA Symposium

Follow NATA on LinkedIn and Twitter

Join NATA's goup on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

News from the Industry: White Paper – Red Cell Salvage: Current Status

Intraoperative Red Cell Salvage (RCS) was introduced in the early 1980s and rapidly gained clinical acceptance. Early RCS was done without cell washing, but washed RCS became the standard of care in cardiac surgery and other procedures.

RCS gained popularity because it did not carry the risk of transfusion-transmitted diseases, notably HIV and hepatitis B and C, and decreased demand for allogeneic blood. While both of these benefits are still true today, the increased safety profile of allogeneic transfusion as well as the presence of stable blood inventories have diminished their importance.

Nevertheless, strong clinical and economic reasons remain to use RCS. This white paper addresses these issues.
Read more on this

News

Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis

On September 25, 2014, Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
Read more on this

From the Literature

Oct 1, 2014

Published: Oct 2014

Galas FR, de Almeida JP, Fukushima JT, et al.

Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial.
J Thorac Cardiovasc Surg 2014;148:1647-1655.

#

NATA REVIEW:
Children undergoing cardiac surgery are at increased risk for perioperative bleeding and allogeneic blood product...
REVIEW by:
D. Faraoni

Published: Sep 2014

Collins PW, Lilley G, Bruynseels D, et al.

Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study.
Blood 2014;124:1727-1736.

#

NATA REVIEW:
In a prospective, observational study, an interdisciplinary group of authors found FIBTEM to predict progression...
REVIEW by:
S. Kozek-Langenecker

Published: Sep 2014

Baron DM, Hochrieser H, Posch M, et al.

Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients.
Br J Anaesth 2014;113:416-423.

#

NATA REVIEW:
In a multinational prospective study with robust and transparent statistical analyses, authors from the European...
REVIEW by:
S. Kozek-Langenecker

Published: Sep 2014

Leijtens B, Kremers van de Hei K, Jansen J, Koeter S

High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline.
Arch Orthop Trauma Surg 2014;134:1335-1341.

#

NATA REVIEW:
Perioperative management of long-term oral anticoagulants is a matter of intense debates, especially with the...
REVIEW by:
D. Faraoni

Published: Aug 2014

Salisbury AC, Reid KJ, Marso SP, et al.

Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals.
J Am Coll Cardiol 2014;64:811-819.

#

NATA REVIEW:
The authors sought to examine the relationship between transfusion and in-hospital mortality in patients with...
REVIEW by:
J.-F. Hardy

Published: Aug 2014

Beyer-Westendorf J, Forster K, Pannach S, et al.

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Blood 2014;124:955-962.

#

NATA REVIEW:
Rivaroxaban is one of the new oral anticoagulants, specifically targeting factor Xa. It was shown to be...
REVIEW by:
M. Levi